12:00 AM
Jun 24, 2013
 |  BC Week In Review  |  Company News  |  Other News

AbbVie, Actavis, Solvay generics, genitourinary news

The U.S. Supreme Court ruled in Federal Trade Commission v. Actavis Inc., et al. that pay-for-delay settlements between branded and generic drug manufacturers are not immune from antitrust litigation. The decision overturns a ruling by the U.S. Court of Appeals for the Eleventh Circuit that a pay-for-delay deal between the pharmaceuticals business of Solvay and generic drug manufacturers, including Actavis, formerly Watson Pharmaceuticals Inc., was...

Read the full 312 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >